Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 871062

I-131 MIBG Therapy in Disseminated Medullary Thyroid Carcinoma


Šnajder, Darija; Mihaljević, Ivan
I-131 MIBG Therapy in Disseminated Medullary Thyroid Carcinoma // 8th International Congress of the Croatian Society of Nuclear Medicine
Šibenik, Hrvatska, 2014. (predavanje, međunarodna recenzija, pp prezentacija, znanstveni)


CROSBI ID: 871062 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
I-131 MIBG Therapy in Disseminated Medullary Thyroid Carcinoma

Autori
Šnajder, Darija ; Mihaljević, Ivan

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, pp prezentacija, znanstveni

Skup
8th International Congress of the Croatian Society of Nuclear Medicine

Mjesto i datum
Šibenik, Hrvatska, 09.05.2014. - 12.05.2014

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
medullary thyroid cancer, MIBG therapy

Sažetak
Background: Medullary thyroid carcinoma (MTC) is a form of thyroid carcinoma which originates from parafollicular C cells which produce calcitonin (hCt), and makes up 3-5% of all thyroid malignancies. Surgery is the most effective therapy, but treatment of metastatic carcinomas is still unsatisfactory. Methods: We overviewed relevant history, clinical findings, laboratory, imaging evaluation and management in 5 female patients with metastatic MTC (aged 15, 64, 70 and 74 years). After total thyroidectomy, the patients received therapy with 100 mCi 131I-MIBG in our Centre. Three of those patients received the therapy twice, second one 3 months up to 1 year after the first cycle, one underwent the therapy three times. All patients had widespread disease with neck recurrences (all 5 cases), liver and bone metastases (2/3 cases) and lung metastases (2 cases). After therapy, whole body scintigraphy was performed ; tumor marker levels (hCt, carcinoembryonic antigen (CEA), neuron specific enolase (NSE), chromogranin A (CgA), pro- gastrin releasing peptide (pro-GRP)) were measured before and after therapy. Results: In two patients we observed a slight decrease in hCt level after first MIBG therapy, in another one a slight decrease in CEA serum level, and no lung metastases were visible on whole body scan after second MIBG therapy. In one of the two remaining cases there was a significant decrease in hCt serum level only after neck dissection, and in the last case further dissemination was observed. Conclusions: In three patients we observed partial response (ie regression), and in the remaining two no response (ie continuation of disease progression).

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Klinički bolnički centar Osijek,
Medicinski fakultet, Osijek

Profili:

Avatar Url Ivan Mihaljević (autor)

Avatar Url Darija Šnajder (autor)


Citiraj ovu publikaciju:

Šnajder, Darija; Mihaljević, Ivan
I-131 MIBG Therapy in Disseminated Medullary Thyroid Carcinoma // 8th International Congress of the Croatian Society of Nuclear Medicine
Šibenik, Hrvatska, 2014. (predavanje, međunarodna recenzija, pp prezentacija, znanstveni)
Šnajder, D. & Mihaljević, I. (2014) I-131 MIBG Therapy in Disseminated Medullary Thyroid Carcinoma. U: 8th International Congress of the Croatian Society of Nuclear Medicine.
@article{article, author = {\v{S}najder, Darija and Mihaljevi\'{c}, Ivan}, year = {2014}, keywords = {medullary thyroid cancer, MIBG therapy}, title = {I-131 MIBG Therapy in Disseminated Medullary Thyroid Carcinoma}, keyword = {medullary thyroid cancer, MIBG therapy}, publisherplace = {\v{S}ibenik, Hrvatska} }
@article{article, author = {\v{S}najder, Darija and Mihaljevi\'{c}, Ivan}, year = {2014}, keywords = {medullary thyroid cancer, MIBG therapy}, title = {I-131 MIBG Therapy in Disseminated Medullary Thyroid Carcinoma}, keyword = {medullary thyroid cancer, MIBG therapy}, publisherplace = {\v{S}ibenik, Hrvatska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font